Primary therapy for acromegaly with somatostatin analogs and a discussion of novel peptide analogs

Reviews in Endocrine and Metabolic Disorders

Volumn 6, Issue 1, 2005, Pages 29-37

  Kleinberg, David L ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BIM 23023; BIM 23197; BIM 23244; BIM 23268; BIM 23454; BIM 53097; BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PEPTIDE DERIVATIVE; SOMATOSTATIN 14; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ACROMEGALY; ADJUVANT THERAPY; CANCER CONTROL; CLINICAL TRIAL; DRUG EFFECT; ENDOCRINE DISEASE; GROWTH HORMONE RELEASE; HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROLACTINOMA; REVIEW; TUMOR VOLUME;

ACROMEGALY; HUMANS; OCTREOTIDE; SOMATOSTATIN;

EID: 17644419085     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11154-005-5222-2     Document Type: Review

References (48)

1. Melmed S, Kleinberg D. Anterior pituitary. In: Larsen PR, Kronenberg HM, Melmed S et al., eds. Williams Textbook of Endocrinology, 10th ed. Philadelphia: Saunders, 2003:177-279.
2. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM. Octreotide treatment of acromegaly: A randomized, multicenter study. Ann Intern Med 1992;117:711-718.
3. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF. Safety and efficacy of long term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - A clinical research center study. J Clin Endocnnol Metab 1995;80:2768-2775.
4. Newman CB, Melmed S, Snyder P, Young W, Klibanski A, Molitch M, Gagel R, Boyd AE, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Jaffe C, Frohman L, Kleinberg DL. Octreotide as primary therapy for acromegaly. 77th Annual Meeting of the Endocrine Society OR4-2. 1995 (Abstract).
5. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G. Effects of treatment with octreotide in acromegalic patients - A multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol 1995;133:430-439.
6. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the international multicenter acromegaly study group. Arch Intern Med 1991;151:1573-1578.
7. Sassolas G, Harris AG, James-Deidier A. Long-term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J Clin Endocrinol Metab 1990;71:391-397.
8. Cheung NW, Taylor L, Boyages SC. An audit of long-term octreotide therapy for acromegaly. Aust NZ J Med 1997;27:12-18.
9. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is effective treatment for acromegaly. J Clin Endocrinol Metab 1995;80:3267-3272.
10. Lancranjan I, Brans C, Grass P. Sandostatin LAR: A promising therapeutic tool in the management of acromegalic patients. Metab 1996;45:67-71.
11. Flogstad AK, Halse J, Bakke S. Sandostatin LAR in acromegalic patients: Long term treatment. J Clin Endocrinol Metab 1997;82:23-28.
12. Davies PH, Stewart SE, Lancranjan L, Sheppard MC, Stewart PM. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 1998;48:311-316.
13. Pagani G, Montini M, Gianola D, Pagani MD, Tengattini F, Dominoni P, Ghilardi G, Cortesi L, Pedroncelli A, Tonnarelli GP. Medical management of acromegaly: Effects of SMS 201-995 in 30 patients. Endocrinol Exp 1990;24:175-185.
14. Tolis G, Yotis A, del Pozo E, Pitoulis S. Therapeutic efficacy of a somatostatin analogue (SMS 201-995) in active acromegaly. J Neurosurg 1986;65:37-40.
15. Tauber JP, Babin TH, Tauber MT. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. J Clin Endocrinol Metab 1989;68:917-924.
16. Sandler LM, Burrin JM, Williams G, Joplin GF, Carr DH, Bloom SR. Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201-995). Clin Endocrinol (Oxf) 1987;26:85-95.
17. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, Beitins IZ. Preoperative treatment of acromegly with long-acting somatostatin analog SMS 201-995: Shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988;67:1040-1048.
18. Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G, Tamburrano G. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 2000;85:4099-H03.
19. Morange I, De Boisvilliers F, Chanson P, Lucas B, DeWailly D, Catus F, Thomas F, Jaquet P. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endo Metab 1994;79:145-151.
20. Cannavo S, Squadrito S, Curto L, Almoto B, Vieni A, Trimarchi F. Results of a two-year treatment with slow release lanreotide in acromegaly. Harm Metab Res 2000;32:224-229.
21. Giusti M, Ciccarelli E, Dallabonzana D, Delitala G, Faglia G, Liuzzi A, Gussoni G, Giordano Disem G. Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Clin Invest 1997;27:277-284.
22. Heron I, Thomas F, Dero M, Cancel A, Ruiz JM, Schatz B, Kuhn JM. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993;76:721-727.
23. Marek J, Hana V, Krsek M, Justova V, Catus F, Thomas F. Long-term treatment of acromegaly with the slow release somatostatin analogue lanreotide. Eur J Endocrinol 1994;131:20-26.
24. Orme S, McNally RJQ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: A retrospective cohort study. J Clin Endo Metab 1998;83:2730-2734.
25. Bates AS, Evans AJ, Jones P, Clayton RN. Assessment of growth hormone status in adults with GH deficiency using serum growth hormone, serum insulin-like growth factor-I and urinary growth hormone excretion. Clin Endocrinol 1995;42:425-430.
26. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Quart J Med 1993;86:293-299.
27. Swearingen B, Barker FGII, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endo Metab 1998;83:3419-3426.
28. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM. Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002;87:4554-4563.
29. Abe T, Ludecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur. J Endocrinol 2001;145:137-145.
30. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3034-3040.
31. Lundin P, Eden EB, Karlsson FA, Burman P. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: Evaluation with serial MR. AJNR Am J Neuroradiol 1997;18:765-772.
32. Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, Papotti M, Mangili F, Terreni MR, Camanni F, Giovanelli M. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab 2001;86:5194-5200.
33. Gilbert J, Ketchen M, Kane P, Mason T, Baister E, Monaghan M, Barr S, Harris PE. The treatment of de novo acromegalic patients with octreotide-LAR: Efficacy, tolerability and cardiovascular effects. Pituitary 2003;6:11-18.
34. Lancranjan I, Bruns C, Grass P. Sandostatin LAR: A promising therapeutic tool in the management of acromegalic patients. Metab 1996;45:67-71.
35. Mangupli R, Lisette A, Ivett C, Paul C, de los Rios Victoria C, Luis CJ. Improvement of acromegaly after octreotide LAR treatment. Pituitary 2003;6:29-34.
36. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: Predictive value of short-term results? J Clin Endocrinol Metab 2003;88:3090-3098.
37. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86:2779-2786.
38. Lucas T, Astorga R, Catala M. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: Effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf) 2003;58:471-481.
39. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146:707-716.
40. Weckbecker G, Briner U, Lewis I, Brans C. SOM230: A new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinol 2002;143:4123-4130.
41. Lewis I, Bauer W, Albert R, Chandramouli N, Pless J, Weckbecker G, Bruns C. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem 2003;46:2334-2344.
42. Murray RD, Kim K, Ren SG, Lewis I, Weckbecker G, Brans C, Melmed S. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 2004;89:3027-3032.
43. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. J Clin Invest 1997;100:2386-2392.
44. van der Haek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, Bruns C, Poon KW, Lewis I, Weckbecker G, Krahnke T, Hofland LJ, Lamberts SW. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004;89:638-645.
45. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24:28-47.
46. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001;86:140-145.
47. Ren SG, Taylor J, Dong J, Yu R, Culler MD, Melmed S. Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab 2003;88:4239-4245.
48. Ren SG, Kim S, Taylor J, Dong J, Moreau JP, Culler MD, Melmed S. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab 2003;88:5414-5421.